• 1. Nickel-catalyzed cross-coupling of aryltrimethylammonium triflates and amines
  Xue-Qi Zhang,Zhong-Xia Wang Org. Biomol. Chem. 2014 12 1448
• 2. Determination of atmospheric isocyanate concentrations by high-performance thin-layer chromatography using 1-(2-pyridyl)piperazine reagent
  P. A. Ellwood,H. L. Hardy,R. F. Walker Analyst 1981 106 85
• 3. Impact of substituents on the crystal structures and anti-leishmanial activity of new homoleptic Bi(iii) dithiocarbamates
  Anamika,Rajan Singh,Krishna K. Manar,Chote Lal Yadav,Akhilesh Kumar,Rakesh K. Singh,Michael. G. B. Drew,Nanhai Singh New J. Chem. 2019 43 16921
• 4. Synthetic, spectral, structural and catalytic activity of infinite 3-D and 2-D copper(ii) coordination polymers for substrate size-dependent catalysis for CO2 conversion
  Bhaskaran,Manoj Trivedi,Anita K. Yadav,Gurmeet Singh,Abhinav Kumar,Girijesh Kumar,Ahmad Husain,Nigam P. Rath Dalton Trans. 2019 48 10078
• 5. Application of electrochemical detection to the measurement of free monomeric aromatic and aliphatic isocyanates in air by high-performance liquid chromatography
  C. J. Warwick,D. A. Bagon,C. J. Purnell Analyst 1981 106 676

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines Pyridinylpiperazines

Recent Advances in the Study of 1-(2-Pyridyl)piperazine (CAS: 34803-66-2) in Chemical Biology and Pharmaceutical Research

1-(2-Pyridyl)piperazine (CAS: 34803-66-2) is a heterocyclic compound that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound, characterized by a piperazine ring linked to a pyridine moiety, serves as a key intermediate in the synthesis of various pharmacologically active molecules. Recent studies have explored its potential as a ligand for receptor binding, its role in drug design, and its applications in medicinal chemistry. This research brief aims to summarize the latest findings related to 1-(2-Pyridyl)piperazine, highlighting its significance in contemporary research.

One of the most notable advancements in the study of 1-(2-Pyridyl)piperazine is its application in the development of novel serotonin receptor ligands. Serotonin receptors play a crucial role in the regulation of mood, cognition, and other neurological functions, making them prime targets for the treatment of psychiatric disorders. Recent research has demonstrated that derivatives of 1-(2-Pyridyl)piperazine exhibit high affinity for serotonin receptor subtypes, particularly 5-HT1A and 5-HT2A. These findings suggest that this compound could serve as a scaffold for the design of new antidepressants and anxiolytics with improved efficacy and reduced side effects.

In addition to its role in serotonin receptor modulation, 1-(2-Pyridyl)piperazine has been investigated for its potential in cancer therapy. A 2023 study published in the Journal of Medicinal Chemistry revealed that certain derivatives of this compound exhibit potent inhibitory effects on histone deacetylases (HDACs), enzymes that are overexpressed in various cancers. The study reported that these derivatives induce apoptosis in cancer cells by modulating epigenetic pathways, offering a promising avenue for the development of targeted anticancer agents. The unique structural features of 1-(2-Pyridyl)piperazine, such as its ability to chelate metal ions, further enhance its utility in drug design.

Another area of interest is the use of 1-(2-Pyridyl)piperazine in the synthesis of metal-organic frameworks (MOFs) for drug delivery applications. Researchers have recently explored the incorporation of this compound into MOFs to improve their stability and drug-loading capacity. A 2022 study in Advanced Materials demonstrated that MOFs functionalized with 1-(2-Pyridyl)piperazine exhibit enhanced controlled release properties, making them suitable for the delivery of chemotherapeutic agents. This innovation addresses one of the key challenges in cancer treatment: achieving targeted and sustained drug release while minimizing systemic toxicity.

Despite these promising developments, challenges remain in the optimization of 1-(2-Pyridyl)piperazine-based compounds for clinical use. Issues such as bioavailability, metabolic stability, and selectivity need to be addressed through further structural modifications and preclinical studies. Recent efforts have focused on the development of prodrug strategies and the use of computational modeling to predict the pharmacokinetic properties of these compounds. For instance, a 2023 study in Drug Discovery Today highlighted the potential of in silico screening to identify optimal derivatives of 1-(2-Pyridyl)piperazine with improved drug-like properties.

In conclusion, 1-(2-Pyridyl)piperazine (CAS: 34803-66-2) continues to be a valuable tool in chemical biology and pharmaceutical research. Its applications span from neurotransmitter receptor modulation to cancer therapy and drug delivery systems, underscoring its versatility. Future research should focus on overcoming the current limitations and translating these findings into clinically viable therapeutics. The ongoing exploration of this compound and its derivatives holds great promise for advancing the field of medicinal chemistry and improving patient outcomes.

• 64728-49-0(1,4-Di(2-pyridyl)piperazine)
• 52266-53-2(1-(Pyridin-2-yl)piperazine Dihydrochloride)
• 129394-11-2(1-(2-Pyridyl)piperazine monohydrochloride)
• 23826-82-6(1,2-Ethanediamine,N1-[2-(diethylamino)ethyl]-N2,N2-dimethyl-N1-2-pyridinyl-)
• 126653-00-7(1-Piperazine-1-yl-isoquinoline)
• 72955-74-9(Piperazine, 1-(2-propynyl)-4-(2-pyridinyl)-)
• 30194-54-8(2-(4-(Pyridin-2-yl)piperazin-1-yl)ethanamine)
• 23826-83-7(1,2-Ethanediamine,N1-[2-(diethylamino)ethyl]-N2,N2-diethyl-N1-2-pyridinyl-)
• 23826-73-5(1,2-Ethanediamine,N1,N1-diethyl-N2-2-pyridinyl-)
• 145208-85-1(Piperazine,1-methyl-4-(2-pyridinyl)-)